4-{(2R-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl} -1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist - Design, synthesis, and characterization

Journal of Medicinal Chemistry

Volumn 47, Issue 27, 2004, Pages 6821-6830

  Chen, Chen ^a   Pontillo, Joseph ^a   Fleck, Beth A ^a   Gao, Yinghong ^a   Wen, Jenny ^a   Tran, Joe A ^a   Tucci, Fabio C ^a   Marinkovic, Dragan ^a   Foster, Alan C ^a   Saunders, John ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 AMINOACETAMIDO) 3 (4 CHLOROPHENYL)PROPIONYL] 1 [2 [(2 THIENYL)ETHYLAMINOMETHYL]PHENYL]PIPERAZINE; 4 [(3 AMINOPROPIONYLAMIDO) 3 (2,4 DICHLOROPHENYL)PROPIONYL] 1 [2 [(2 THIENYL)ETHYLAMINOMETHYL]PHENYL]PIPERAZINE; 4 [(3 AMINOPROPIONYLAMIDO) 3 (4 CHLOROPHENYL)PROPIONYL] 1 [2 [(2 THIENYL)ETHYLAMINOMETHYL]PHENYL]PIPERAZINE; ALPHA INTERMEDIN; CYCLIC AMP; MCL 0129; MELANOCORTIN 4 RECEPTOR; ML 253764; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; PIPERAZINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CACHEXIA; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ANIMALS; CACHEXIA; CYCLIC AMP; DRUG DESIGN; HUMANS; MALE; MELANOCYTE-STIMULATING HORMONES; MICE; MODELS, MOLECULAR; MUTAGENESIS; PIPERAZINES; RECEPTOR, MELANOCORTIN, TYPE 4; THIOPHENES;

EID: 19944429810     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049278i     Document Type: Article

References (57)

1. (a) Beck-Sickinger, A. G. Structural characterization and binding sites of G-protein-coupled receptors. Drug Discov. Today 1996, 1, 502-513.
2. (b) Ballesteros, J.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
3. (a) Horn, F.; Weare, J.; Beukers, M. W.; Horsch, S.; Bairoch, A. GPCRDB: An information system for G protein-coupled receptors. Nucleic Acids Res. 1998, 26, 275-279.
4. (b) Gutkind, J. S.; Marinissen, M. J. G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol. Sci. 2001, 22, 368-376.
5. (a) Marshall, G. R. Peptide interactions with G-protein coupled receptors. Biopolymers (Pept. Sci.), 2001, 60, 246-277.
6. (b) Freidinger, R. M. Nonpeptidic ligands for peptide and protein receptors. Curr. Opin. Chem. Biol. 1999, 3, 395-406.
7. Palczewski, K; Kumasaka, T.; Hori, T.; Nehnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
8. Lu, Z.-L.; Saldanha, J. W.; Hulme, E. C. Seven-transmembrane receptors: Crystals clarify. Trends Pharmacol. Sci. 2002, 23, 140-146.
9. Probst, W. C.; Snyder, L. A.; Schuster, D. I.; Brosius, J.; Sealfon, S. C. Sequence alignment of the G protein-coupled receptor superfamily. DNA Cell Biol. 1992, 11, 1-20.
10. (a) Shacham, S.; Topf, M.; Avisar, N.; Glaser, F.; Marantz, Y.; Bar-Haim, S.; Noiman, S.; Naor, Z.; Becker, O. M. Modeling the 3D structure of GPCRs from sequence. Med. Res. Rev. 2001, 21, 472-483.
11. (b) Archer, E.; Maigret, B.; Escrieut, C.; Pradayrol, L.; Fourmy, D. Rhodopsin crystal: New template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci. 2003, 24, 36-40.
12. (a) Strader, C. D.; Fong, T. M.; Tota, M. R.; Underwood, D.; Dixon, R. A. Structure and function of G protein-coupled receptors. Anna. Rev. Biochem. 1994, 63, 101-132.
13. (b) Kristiansen, K. Molecular mechanism of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: Molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 2004, 103, 21-80.
14. (a) Cascieri, M. A.; Fong, T. M.; Strader, C. D. Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. J. Pharmacol. Tox. Methods 1995, 33, 179-185.
15. (b) Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
16. 1a adrenergic receptor using homology modeling and molecular docking. Biochem. Biophy. Res. Commun. 2004, 319, 493-500.
17. Wikberg, J. E. S. Melanocortin receptors: Perspectives for novel drugs. new aspects on the melanocortins and their receptors. Eur. J. Pharmacol. 1999, 375, 295-310.
18. Wikberg, J. E. S.; Muceniece, R.; Mandrika, I.; Prusis, P.; Post, C.; Skottner, A. New aspects on the melanocortins and their receptors. Pharmacol. Res. 2000, 42, 393-420.
19. Goodfellow, V.; Saunders, J. The melanocortin system and its role in obesity and cachexia. Curr. Topic Med. Chem. 2003, 3, 855-883.
20. Haskell-Luevano, C.; Hendrata, S.; North, C.; Sawyer, T. K.; Hadley, M. E.; Hruby, V.; Dickinson, C.; Gantz, I. Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J. Med. Chem. 1997, 40, 2133-2139.
21. Millhauser, G. L.; Mcnulty, J. C.; Jackson, P. J.; Thompson, D. A.; Barsh, G. S.; Gabtz, I. Loops and links: Structural insights into the remarkable function of the agouti-related protein. Ann. N. Y. Acad. Sci. 2003, 994, 27-35.
22. Kiefer, L. L.; Veal, J. M.; Mountjoy, K. G.; Wilkison, W. O. Melanocortin receptor binding determinants in the agouti protein. Biochemistry 1998, 37, 991-997.
23. Yang, Y. K.; Harmon, C. M. Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes. Rev. 2003, 4, 239-248.
24. (a) Marks, D. L.; Ling, N.; Cone, R. Role of the central melanocortin system in cachexia. Cancer Res. 2001, 61, 1432-1438.
25. (b) Wisse, B. E.; Frayo, R. S.; Schwartz, M. W.; Cummings, D. E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001, 142, 3292-3301.
26. Inui, A. Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J. Clin. 2002, 52, 72-91.
27. Vos, T. J.; Caracoti, A.; Che, J.; Dai, M.; Farrer, C. A.; Forsyth, N. E.; Drabic, S. V.; Horlick, R. A.; Lamppu, D.; Yowe, D. L.; Balani, S.; Li, P.; Zeng, H.; Joseph, I. B. J. K.; Rodriguez, L. E.; Claiborne, C. F. The identification of 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-4, 5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J. Med. Chem. 2004, 47, 1602-1604.
28. Arasasingham, P. A.; Fotsch, C.; Ouyang, X.; Norman, M. H.; Kelly, M. G.; Stark, K. L.; Karbon, B.; Hale, C.; Baumgartner, J. W.; Zambrano, M.; Cheetham, J.; Tamayo, N. A. Structure-activity relationship of (1-aryl-2- piperazinylethyl)piperazines: Antagonists for the AGRP/melanocortin receptor binding. J. Med. Chem. 2003, 46, 9-11.
29. Chaki, S.; Hirota, S.; Funakoshi, T.; Suzuki, Y.; Suetake, S.; Okubo, T.; Ishii, T.; Nakazato, A.; Okuyama, S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl) ethyl]-4-[4-(2-methoxy-naphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J. Pharmacol. Exp. Ther. 2003, 304, 818-826.
30. Marsilje, T. H.; Roses, J. B.; Calderwood, E. F.; Stroud, S. G.; Forsyth, N. E.; Blackburn, C.; Yowe, D. L.; Miao, W.; Drabic, S. V.; Bohane, M. D.; Daniels, J. S.; Li, P.; Wu, L.; Patane, M. A.; Claiborne, C. F. Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R). Bioorg. Med. Chem. Lett. 2004, 14, 3721-3725.
31. Sebhat, I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; Johnston, D. B. R.; Bakshi, R.; Palucki, B.; Weinberg, D. H.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Stearns, R. A.; Miller, R. R.; Tamvakopoulos, C.; Strack, A. M.; McGowan, E.; Cashen, D. E.; Drisko, J. E.; Hom, G. J.; Howard, A. D.; MacIntyre, D. E.; van der Ploeg, L. H. T.; Patchett, A. A.; Nargund, R. P. Design and pharmacology of N-[(3.R)-1,2,3,4-tetrahydroisoquinolinium-3- ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4cyclohexyl-4-(1H-1,2, 4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. 2002, 45, 4589-4593.
32. (a) Pan, K.; Scott, M. K.; Lee, D. H. S.; Fitzpatrick, L. J.; Crooke, J. J.; Rivero, R. A.; Rosenthal, D. I.; Vaidya, A. H.; Zhao, B.; Reitz, A. B. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg. Med. Chem. 2003, 11, 185-192.
33. (b) Herpin, T. F.; Yu, G.; Carlson, K. E.; Morton, G. C.; Wu, X.; Kang, L.; Tuerdi, H.; Khanna, A.; Tokarski, J. S.; Lawrence, R. M.; Macor, J. E. Discovery of tyrosine-based potent and selective melanocortin-1 receptor small molecule agonists with antiinflammatory properties. J. Med. Chem. 2003, 46, 1123-1126.
34. 2. Bioorg. Med. Chem. Lett. 2003, 13, 2337-2340.
35. (d) Dyck, B.; Parker, J.; Philips, T.; Carter, L.; Murphy, B.; Summers, R.; Hermann, J.; Baker, T.; Cismowski, M.; Saunders, J.; Goodfellow, V. Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3793-3796.
36. (e) Ruel, R.; Herpin, T. F.; Iben, L.; Luo, G.; Martel, A.; Mason, H.; Mattson, G.; Poirier, B.; Ruediger, E. H.; Shi, D.; Thibault, C.; Yu, G.; Zimanyi, I. A.; Poindexter, G. S.; Macor, J. E. β-Alanine dipeptides as MC4R agonists. Bioorg. Med. Chem. Lett. 2003, 13, 4341-4344.
37. (f) Ujjainwalla, F.; Warner, D.; Walsh, T. F.; Wyvratt, M. J.; Zhou, C.; Yang, L.; Kalyani, R. N.; MacNeil, T.; Van der Ploeg, L. H. T.; Rosenblum, C. I.; Tang, R.; Vongs, A.; Weinberg, D. H.; Goulet, M. T. Design and synthesis of melanocortin subtype-4 receptor agonists: Evolution of the pyridazinone archetype. Bioorg. Med. Chem. Lett. 2003, 13, 4431-4435.
38. (g) Richardson, T. I.; Ornstein, P. L.; Briner, K.; Fisher, M. J.; Backer, R. T.; Biggers, C. K.; Clay, M. P.; Emmerson, P. J.; Hertel, L. W.; Hsiung, H. M.; Husain, S.; Kahl, S. D.; Lee, J. A.; Lindstrom, T. D.; Martinelli, M. J.; Mayer, J. P.; Mullaney, J. T.; O'Brien, T. P.; Pawlak, J. M.; Revell, K. D.; Shah, J.; Zgombick, J. M.; Herr, R. J.; Melekhov, A.; Sampson, P. B.; King, C.-H. R. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem. 2004, 47, 744-755.
39. (h) Xi, N.; Hale, C.; Kelly, M. G.; Norman, M. H.; Stec, M.; Xu, S.; Baumgartner, J. W.; Fotsch, C. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg. Med. Chem. Lett. 2004, 14, 377-381.
40. (i) Mutulis, F.; Yahorava, S.; Mutule, I.; Yahorau, A.; Liepinsh, E.; Kopantshuk, S.; Veiksina, S.; Tars, K.; Belyakov, S.; Mishnev, A.; Rinken, A.; Wikberg, J. E. S. New substituted piperazines as ligands for the melanocortin receptors. Correlation to the X-ray structure of "THIQ". J. Med. Chem. 2004, 47, 4613-4626.
41. Patchett, A. A.; Nargund, R. P. Chapter 26: Privileged structures. Ann. Rep. Med. Chem. 2000, 35, 289-298.
42. Pontillo, J.; Tran, J. A.; Arellano, M.; Fleck, B. A.; Huntley, R.; Marinkovic, D.; Lanier, M.; Nelson, J.; Parker, J.; Saunders, J.; Tucci, F. C.; Jiang, W.; Chen, C. W.; White, N. S.; Foster, A. C.; Chen, C. Structure-activity relationships of peperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2004, 14, 4417-4423.
43. Nickolls, S. A.; Cismowski, M. I.; Wang, X.; Wolff, M.; Conlon, P. J.; Maki, R. A. Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity. J. Pharmacol. Exp. Ther. 2003, 304, 1217-1227.
44. In a separated study in mice, measurement of 10 in the portal vein after an oral dose suggested 4% absorption.
45. Holder, J. R.; Haskell-Luevano, C. Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies. Med. Res. Rev. 2004, 24, 325-356.
46. 2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 1995, 38, 3545-3461.
47. Yang, Y-k.; Fong, T. M.; Dickinson, C. J.; Mao, C.; Li, J.-M.; Tota, M. R.; Mosley, R.; Van der Ploeg, L. H. T.; Gantz, I. Molecular determination of ligand binding to the human melanocortin receptor. Biochemistry 2000, 39, 14900-14911.
48. Haskell-Luevano, Cone, R. D.; Monck, E. K.; Wan, Y.-P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: Identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry, 2001, 40, 6164-6179.
49. Bednarek, M. A.; MacNeil, T.; Tang, R.; Kalyani, R. N. Potent and selective peptide agonists of α-melanotropin action at human melanocortin receptor 4: Their synthesis and biological evaluation in Vitro. Biochem. Biophy. Res. Commun. 2001, 286, 641-645.
50. Sun, H.; Greeley, D. N.; Chu, X.-J.; Cheung, A.; Danho, W.; Swistok, J.; Wang, Y.; Zhao, C.; Chen, L.; Fry, D. C. A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides. Bioorg. Med. Chem. 2004, 12, 2671-2677.
51. Cheung, A. W-H.; Danho, W.; Swistok, J.; Qi, L.; Kurylko, G.; Franco, L.; Yagaloff, K.; Chen, L. Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: Arginine substitution. Bioorg. Med. Chem. Lett. 2002, 12, 2407-2410.
52. (a) X.; Wang, Z.; Dong, W.; Ling, L.; Yang, H.; Chen, Modeling, R.; docking of the three-dimensional structure of the human melanocortin 4 receptor. J. Protein Chem. 2003, 22, 335-344.
53. (b) Bondensgaard, K.; Ankersen, M.; Thogensen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structure by G-protein coupled receptors. J. Med. Chem. 2004, 47, 888-899. Note: The numbering for the human MC4 receptor in this paper is off 8, which matches the mouse MC4 receptor.
54. (c) Wilczynski, A.; Wang, X. S.; Joseph, C. G.; Xiang, Z.; Bauzo, R. M.; Scott, J. W.; Sorensen, N. B.; Shaw, A. M.; Millard, W. J.; Richards, N. G.; Haskell-Luevano, C. Identification of putative agouti-related protein (87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. J. Med. Chem. 2004, 47, 2194-2207.
55. Karnik, S. S.; Gogonea, C.; Patil, S.; Saad, Y.; Takezako, T. Activation of G-protein-coupled receptors: A common molecular mechanism. Trends Endocrinol. Metab. 2003, 14, 431-437.
56. i of 60 nM; see ref 24g.
57. For assay conditions, see: Guo, Z.; Zhu, Y.-F.; Gross, T. D.; Tucci, F. C.; Gao, Y.; Moorjani, M.; Connors, P. C., Jr.; Rowbottom, M. W.; Chen, Y.; Struthers, R. S.; Xie, Q.; Saunders, J.; Reinhart, G.; Chen, T. K.; Bonneville, A. L. K.; Chen, C. Synthesis and structure-activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotropin-releasing hormone receptor antagonists. J. Med. Chem. 2004, 47, 1259-1271.